Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
53.84B | 53.56B | 53.72B | 62.98B | 63.49B | 56.64B | Gross Profit |
11.69B | 11.82B | 11.51B | 12.34B | 13.42B | 10.44B | EBIT |
3.82B | 3.82B | 3.46B | 4.68B | 5.30B | 3.46B | EBITDA |
4.82B | 4.71B | 4.46B | 5.45B | 8.60B | 4.26B | Net Income Common Stockholders |
2.72B | 2.77B | 3.26B | 3.13B | 6.54B | 2.81B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
2.89B | 3.25B | 3.23B | 3.15B | 4.30B | 4.86B | Total Assets |
38.93B | 39.91B | 37.00B | 38.59B | 38.61B | 34.68B | Total Debt |
10.90B | 10.90B | 10.74B | 11.01B | 7.49B | 6.22B | Net Debt |
8.02B | 7.66B | 7.51B | 7.87B | 3.19B | 1.35B | Total Liabilities |
40.00B | 41.23B | 38.07B | 41.51B | 40.26B | 36.91B | Stockholders Equity |
-1.07B | -1.32B | -1.07B | -2.92B | -1.65B | -2.23B |
Cash Flow | Free Cash Flow | ||||
3.27B | 3.16B | 2.96B | 3.67B | 5.83B | 3.74B | Operating Cash Flow |
4.00B | 3.75B | 3.57B | 4.46B | 6.41B | 4.32B | Investing Cash Flow |
-718.00M | -646.00M | -590.00M | -3.55B | -1.01B | -1.02B | Financing Cash Flow |
-2.81B | -3.08B | -2.89B | -2.07B | -5.96B | -2.97B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $21.93B | 18.74 | 108.51% | 1.96% | 5.00% | 22.19% | |
75 Outperform | $18.09B | 148.79 | 9.76% | ― | 10.85% | 30.85% | |
72 Outperform | $77.75B | 18.15 | -179.12% | 1.64% | 7.67% | ― | |
70 Neutral | $19.35B | 10.54 | 28.45% | ― | 21.22% | ― | |
68 Neutral | $26.95B | 18.35 | -109.27% | 2.24% | 36.29% | ― | |
64 Neutral | $23.65B | 9.70 | 84.33% | 4.49% | 2.08% | -12.41% | |
62 Neutral | $11.81B | 10.34 | -7.44% | 2.91% | 7.41% | -7.93% |
On February 21, 2025, HP Inc. expanded its Board of Directors by appointing Gianluca Pettiti, an executive from Thermo Fisher Scientific, as an independent director. This move necessitated an amendment to the company’s bylaws, increasing the number of authorized directorships from 14 to 15. Mr. Pettiti will serve on the Finance, Investment and Technology Committee and the HR and Compensation Committee, receiving compensation consistent with other non-employee directors.